REMARKS

Applicant respectfully requests entry of the above amendments. Claims 11, 13, 15-16, 19, 28-29 are pending in this application. Claims 15, 16, and 28 are currently amended. Claims 11, 13, 19, and 29 are previously presented. Claims 1-10, 12, 14, 17-18, and 20-27 were previously canceled. No new matter was added in this amendment.

Claim Rejections (§112, 2nd ¶):

The Office Action rejected claims 15 and 16 relative to \$112, 2^{nd} ¶, as being indefinite (i.e., improper dependency) and claim 19 for depending from claim 16. Applicant has amended claims 15 and 16 to ensure proper dependency, thereby rendering the rejection moot. Applicant requests that the \$112 rejection be withdrawn.

Secondly, the Office Action rejected claim 28 relative to §112, 2nd ¶, as being indefinite (i.e., improper basis). Applicant has amended claim 28 by including Formula (1a) within the breadth of the claim to ensure proper basis, thereby rendering the rejection moot. Applicant requests that this §112 rejection be withdrawn.

IDS:

During prosecution of an equivalent patent application in Japan, the JPO cited JPS59152320 as art against the application. The JP citation is equivalent to EP0119737 which was previously disclosed to the USPTO. However, the JP citation recites additional subject matter that was not present in the EP application. Therefore, Applicant is submitting a translated version of JPS59152320.

Attorney Docket No. PC25670A U.S. Patent Appl. No. 10/588,070

Conclusion:

Applicant, having responded to all points and concerns raised by the Office Action, believes the application to be in condition for allowance. An early and favorable action is requested.

Respectfully submitted,

2-13-2012

Date

Paul M. Misiak Attorney for Applicants Reg. No. 58,310

Pfizer Inc.
Patent Department
7000 Portage Rd. KZO-300-106SW
Kalamazoo, MI 49001
(269) 833-4604 (phone)
(269) 833-8897 (facsimile)